{"DataElement":{"publicId":"13752211","version":"1","preferredName":"Modified Toxicity Criteria Injection Site Reaction Condition Grade","preferredDefinition":"A description of the modified toxicity criteria for the injection site reaction grade.","longName":"13752139v1.00:13752163v1.00","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"13752139","version":"1","preferredName":"National Marrow Donor Program Modified Toxicity Criteria Injection Site Reaction Condition","preferredDefinition":"Criteria established by the National Marrow Donor Program (NMDP) that assesses potential toxicities following peripheral blood or bone marrow stem cell collection from donors and includes: fever in absence of infections; fatigue; rashes; injection site reaction; nausea; vomiting; loss of appetite; inability to sleep; dizziness, vertigo, or lightheadedness; fainting; and pain.:An intense reaction (usually immunologic) developing at the site of injection_A state of being, such as a state of health.","longName":"13751560v1.00:13752138v1.00","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"13751560","version":"1","preferredName":"National Marrow Donor Program Modified Toxicity Criteria","preferredDefinition":"Criteria established by the National Marrow Donor Program (NMDP) that assesses potential toxicities following peripheral blood or bone marrow stem cell collection from donors and includes: fever in absence of infections; fatigue; rashes; injection site reaction; nausea; vomiting; loss of appetite; inability to sleep; dizziness, vertigo, or lightheadedness; fainting; and pain.","longName":"C199478","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"National Marrow Donor Program Modified Toxicity Criteria","conceptCode":"C199478","definition":"Criteria established by the National Marrow Donor Program (NMDP) that assesses potential toxicities following peripheral blood or bone marrow stem cell collection from donors and includes: fever in absence of infections; fatigue; rashes; injection site reaction; nausea; vomiting; loss of appetite; inability to sleep; dizziness, vertigo, or lightheadedness; fainting; and pain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCED37C0-8F10-1878-E053-731AD00AD0C4","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"13752138","version":"1","preferredName":"Injection Site Reaction Condition","preferredDefinition":"An intense reaction (usually immunologic) developing at the site of injection_A state of being, such as a state of health.","longName":"C3508:C25457","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Injection Site Reaction","conceptCode":"C3508","definition":"An intense reaction (usually immunologic) developing at the site of injection","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Condition","conceptCode":"C25457","definition":"A state of being, such as a state of health.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEE0527-13EC-3907-E053-731AD00A284E","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEE0527-13ED-3907-E053-731AD00A284E","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-07-06","changeDescription":null,"administrativeNotes":"2023.7.6 Released per review. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"13752163","version":"1","preferredName":"National Marrow Donor Program Modified Toxicity Criteria Injection Site Reaction Grade","preferredDefinition":"Criteria established by the National Marrow Donor Program (NMDP) that assesses potential toxicities following peripheral blood or bone marrow stem cell collection from donors and includes: fever in absence of infections; fatigue; rashes; injection site reaction; nausea; vomiting; loss of appetite; inability to sleep; dizziness, vertigo, or lightheadedness; fainting; and pain._An intense reaction (usually immunologic) developing at the site of injection_A position on a scale of intensity or amount or quality.","longName":"13752163v1.00","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"120","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"None","valueDescription":null,"ValueMeaning":{"publicId":"13707077","version":"1","preferredName":"None","longName":"13707077v1.00","preferredDefinition":"None (grade 0)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC997DFD-C173-2136-E053-731AD00AF445","latestVersionIndicator":"Yes","beginDate":"2023-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-26","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCEEF1F4-65AC-66E0-E053-731AD00AECD6","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","deletedIndicator":"No"},{"value":"Pain and swelling with inflammation or phlebitis","valueDescription":null,"ValueMeaning":{"publicId":"13752187","version":"1","preferredName":"Pain and swelling with inflammation or phlebitis","longName":"13752187v1.00","preferredDefinition":"Pain and swelling with inflammation or phlebitis (grade 2)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEEF1F4-65AB-66E0-E053-731AD00AECD6","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCEEF1F4-65AE-66E0-E053-731AD00AECD6","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","deletedIndicator":"No"},{"value":"Pain; itching; erythema","valueDescription":null,"ValueMeaning":{"publicId":"13752197","version":"1","preferredName":"Pain; itching; erythema","longName":"13752197v1.00","preferredDefinition":"Pain; itching; erythema (grade 1)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEF4A5E-0E8F-753A-E053-731AD00A182B","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCEF4A5E-0E90-753A-E053-731AD00A182B","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","deletedIndicator":"No"},{"value":"Ulceration or necrosis that is severe; operative intervention indicated","valueDescription":null,"ValueMeaning":{"publicId":"13752198","version":"1","preferredName":"Ulceration or necrosis that is severe; operative intervention indicated","longName":"13752198v1.00","preferredDefinition":"Ulceration or necrosis that is severe; operative intervention indicated (grade 3))","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEF4E4F-EEE5-75B1-E053-731AD00A56AE","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCEF4E4F-EEE6-75B1-E053-731AD00A56AE","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"13752162","version":"1","preferredName":"National Marrow Donor Program Modified Toxicity Criteria Injection Site Reaction Grade","preferredDefinition":"Criteria established by the National Marrow Donor Program (NMDP) that assesses potential toxicities following peripheral blood or bone marrow stem cell collection from donors and includes: fever in absence of infections; fatigue; rashes; injection site reaction; nausea; vomiting; loss of appetite; inability to sleep; dizziness, vertigo, or lightheadedness; fainting; and pain._An intense reaction (usually immunologic) developing at the site of injection_A position on a scale of intensity or amount or quality.","longName":"13752162v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"National Marrow Donor Program Modified Toxicity Criteria","conceptCode":"C199478","definition":"Criteria established by the National Marrow Donor Program (NMDP) that assesses potential toxicities following peripheral blood or bone marrow stem cell collection from donors and includes: fever in absence of infections; fatigue; rashes; injection site reaction; nausea; vomiting; loss of appetite; inability to sleep; dizziness, vertigo, or lightheadedness; fainting; and pain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Injection Site Reaction","conceptCode":"C3508","definition":"An intense reaction (usually immunologic) developing at the site of injection","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Grade","conceptCode":"C48309","definition":"A position on a scale of intensity or amount or quality.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEE4739-90E6-41F0-E053-731AD00A25A8","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEE4739-90E7-41F0-E053-731AD00A25A8","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-07-06","changeDescription":null,"administrativeNotes":"2023.7.6 Released per review. ak2023.5.30 Created per ticket request CADSR0002455. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"What was the modified toxicity criteria for the injection site reaction grade?","url":null,"context":"NHLBI"},{"name":"NMDP Text 1","type":"Alternate Question Text","description":"Injection site reaction (filgrastim or similar, IV, or marrow collection)","url":null,"context":"NHLBI"},{"name":"NMDP Text 2","type":"Application Standard Question Text","description":"Injection site reaction","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEFD48A-7CDB-0C35-E053-731AD00AE7D5","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-30","modifiedBy":"KUMMEROA","dateModified":"2023-07-06","changeDescription":null,"administrativeNotes":"2023.7.6 Released per review. ak","unresolvedIssues":null,"deletedIndicator":"No"}}